Cover; Half Title; Title Page; Copyright Page; Dedication; Table of Contents; Foreword; Preface; Acknowledgments; Editors; Contributors; Section I : Nanotechnology-Based Approaches to Target Cancer; Chapter 1: Nanomedicines for Cancer; 1.1 Introduction; 1.2 Nanomedicines in Clinical Use and Under Clinical Trials; 1.2.1 Liposome-Based Nanomedicines; 1.2.2 Polymer-Based Nanomedicines; 1.2.3 Protein-Based Nanomedicines; 1.2.4 Micelles-Based Nanomedicines; 1.2.5 Nanotechnology-Based Miscellaneous Nanomedicines; 1.3 Targeting Mechanism of Nanomedicines; 1.3.1 Passive Targeting

1.3.2 Active Targeting1.3.3 Stimuli-Responsive Nanomedicine; 1.4 Design Aspect of Nanomedicines; 1.4.1 Vascular Transport; 1.4.2 Transvascular Transport; 1.4.3 Interstitial Transport; 1.4.4 Intracellular Transport; 1.5 Enhancing Nanomedicine Translation through Clinically Relevant Models; 1.5.1 Standard Xenograft Models with Human Stroma Components; 1.5.2 Patient-Derived Tumor Xenograft (PDX) Model; 1.5.3 Humanized PDX Model; 1.5.4 Human Metastatic Site Model; 1.6 Challenges and Current Limitations; 1.7 Advantages and Disadvantages of Nanotechnology; 1.8 Conclusion; References

Chapter 2: Effect of Nanocarrier Size/Surface on Molecular Targeting in Cancer2.1 Introduction; 2.2 Particle Size in Tumor Targeting; 2.2.1 Tumor Type and Pore Cutoff Size; 2.2.2 Circulation in Bloodstream; 2.2.3 Nanoparticle Trafficking and Tumor Internalization; 2.2.4 Cellular Uptake and Cell-Particle Interactions; 2.3 Particle Shape on Tumor Targeting; 2.3.1 Circulation in Bloodstream; 2.3.2 Nanoparticle Transportation and Tumor Internalization; 2.3.3 Cellular Uptake and Cell-Particle Interactions; 2.4 Influence of Nanocarrier Surface Properties on Tumor Targeting

2.4.1 Circulation in Bloodstream2.4.2 Nanoparticle Transportation and Tumor Internalization; 2.4.3 Surface Functionalization with Targeting Tumors; 2.5 Conclusion; References; Chapter 3: Nanocarrier Systems for Anticancer Drug Delivery at the Subcellular Level; 3.1 Introduction; 3.2 Mitochondrial Targeted Drug Delivery; 3.2.1 Mitochondria and Cancer Therapy; 3.2.2 Mitochondrial Drug Delivery; 3.2.2.1 Mitochondriotropic Conjugated Nanocarriers; 3.2.2.2 Mitochondrial-Penetrating Peptide (MPP) Conjugated Nanocarriers; 3.2.2.3 Mitochondrial Targeting Signal (MTS) Conjugated Nanocarriers

3.3 Nuclear Targeted Drug Delivery3.3.1 The Nucleus: Role in Cancer Treatment; 3.3.2 Nuclear Drug Delivery; 3.3.2.1 Nuclear Localization Signal (NLS) Conjugated Nanocarriers; 3.3.2.2 Other Approaches; 3.4 Lysosomal Targeted Drug Delivery; 3.4.1 Lysosomes; 3.4.2 Lysosomal Cell Death; 3.4.3 Lysosomal Drug Delivery; 3.4.3.1 Nanocarriers Containing Lysosomotropic Agents; 3.4.3.2 Nanocarriers Modified with Cathepsin-Specific Substrates; 3.4.3.3 Ceramide Containing Nanocarriers; 3.4.3.4 Metal Nanoparticles; 3.4.3.5 pH-Responsive Nanocarriers; 3.5 Endoplasmic Reticulum (ER) Targeted Drug Delivery

The field of molecular medicine covers the medical interventions targeting molecular structures and mechanisms that are involved in disease progression. In cancer, several molecular mechanisms have been shown to impact its progression, aggressiveness and chemoresistance. Increasing evidence demonstrates the role of nanotechnology and outcome of molecular therapy. Several books have discussed molecular biology and mechanisms involved in cancer, but this text gives an account of molecular therapeutics in cancer relating to advancements of nanotechnology. It provides a description of the multidisciplinary field of molecular medicines and its targeted delivery to cancer using nanotechnology.

OCLC-licensed vendor bibliographic record.